Clough Global Allocation Fund Stock News

DENVER, June 23, 2021 /PRNewswire/ -- Clough Global Dividend and Income Fund (the "Fund") is pleased to announce the successful completion of its rights offering, and the preliminary results thereof.

We recently touched on rights offerings and tender offers, and today we'll discuss at-the-market offerings.

DENVER, May 28, 2021 /PRNewswire/ -- Today, the Clough Global Dividend and Income Fund (NYSE MKT: GLV) (the "Fund"), a closed-end fund, paid a monthly distribution on its common stock of $0.0967 per

Evaluating CEFs: Global Exposure And Declining NAV Don't Pair Well For GLV

DENVER, May 10, 2021 /PRNewswire/ -- The Board of Trustees of the Clough Global Dividend and Income Fund ("GLV" or the "Fund") has authorized and set the terms for a transferable rights offering ("th

DENVER, April 9, 2021 /PRNewswire/ -- Today, the Board of Trustees (the "Board") for the Clough Global Dividend and Income Fund (the "Fund") has declared a monthly cash distribution of $0.0967 per co

The Clough funds all have impressive records. GLV previously paid a higher distribution yield even though it didn't earn as much as its two siblings, GLO and GLQ. That's been rectified with the big di

Clough operates three CEFs, they all have a broad investment policy allowing them to invest in just about any manner.

Today, the Board of Trustees (the "Board") for the Clough Global Dividend and Income Fund (the "Fund") has declared a monthly cash distribution of $0.1008 per common share, payable on the dates noted

On June 30, 2020, the Clough Global Dividend and Income Fund (NYSE MKT: GLV) (the "Fund"), a closed-end fund, paid a monthly distribution on its common stock of $0.1008 per share to shareholders of re

The Board of Trustees of the Clough Global Dividend and Income Fund, Clough Global Equity Fund and Clough Global Opportunities Fund (each, a "Fund" and together, the "Funds") have determined it is adv

This is a weekly series focused on analyzing the previous week’s economic data releases. The objective is to concentrate on leading indicators of economic activ

Next-gen cancer biotech Checkmate Pharmaceuticals has grabbed a healthy series C round toward work on its all-or-nothing immuno-oncology hopeful.